ArticleVaccine2018
Model-estimated effectiveness of single dose 9-valent HPV vaccination for HIV-positive and HIV-negative females in South Africa.
Article in Vaccine, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 2 syntheses or guidelines pooled it, 47 citations in OpenAlex.
- Inclusion of marginalized populations in HPV vaccine modeling: A systematic review.Preventive medicine · 2024Pooled it
- Treatment of pre- and confirmed cervical cancer in HIV-seropositive women from developing countries: a systematic review.Systematic reviews · 2020Pooled it
- HPV genotype distribution and risk factors for cervical dysplasia among HPV-positive women with or without HIV infection in Shanghai, China.BMC infectious diseases · 2026Article
- The impact of HIV on cervical cancer elimination in KwaZulu-Natal: a comparative modeling analysis.Journal of the National Cancer Institute · 2026Article
- Health and economic impacts of Vaccae vaccination incorporating active case finding in India and South Africa: a modelling study.BMJ public health · 2024Article
- Single-dose human papillomavirus vaccination: an update.Journal of the National Cancer Institute. Monographs · 2024Article
- Inferring the natural history of HPV from global cancer registries: insights from a multi-country calibration.Scientific reports · 2024Article
- FAM19A4 and hsa-miR124-2 Double Methylation as Screening for ASC-H- and CIN1 HPV-Positive Women.Pathogens (Basel, Switzerland) · 2024Article
- Human papillomavirus genotype distribution patterns in Zimbabwe; is the bivalent vaccine sufficient?Intervirology · 2024Review
- Cost-effectiveness of single-visit cervical cancer screening in KwaZulu-Natal, South Africa: a model-based analysis accounting for the HIV epidemic.Frontiers in oncology · 2024Article
- Article
- Exploring computer-aided health decision-making on cervical cancer interventions through deliberative interviews in Ethiopia.NPJ digital medicine · 2023Article
- Optimal allocation strategies for HPV vaccination introduction and expansion in China accommodated to different supply and dose schedule scenarios: A modelling study.EClinicalMedicine · 2023Article
- Leveraging health infrastructure to optimize HPV vaccination for adolescents in Zambia: Protocol for an implementation study.PloS one · 2023Article
- Joint modeling HIV and HPV using a new hybrid agent-based network and compartmental simulation technique.PloS one · 2023Article
- Estimating the effect of HIV on cervical cancer elimination in South Africa: Comparative modelling of the impact of vaccination and screening.EClinicalMedicine · 2022Article
- Mathematical Models for Evaluating Effectiveness and Cost-Effectiveness of Cervical Cancer Control Policies in Populations Including Women Living With Human Immunodeficiency Virus: A Scoping Review.Value in health regional issues · 2022Article
- Modelling cervical cancer elimination using single-visit screening and treatment strategies in the context of high HIV prevalence: estimates for KwaZulu-Natal, South Africa.Journal of the International AIDS Society · 2022Article
- Age-specific burden of cervical cancer associated with HIV: A global analysis with a focus on sub-Saharan Africa.International journal of cancer · 2022Article
- Impact of catch-up human papillomavirus vaccination on cervical cancer incidence in Kenya: A mathematical modeling evaluation of HPV vaccination strategies in the context of moderate HIV prevalence.EClinicalMedicine · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 2 countries.
Funding
Abstract
backgroundWomen in sub-Saharan Africa have high dual burden of HPV and HIV infections, which can interact to increase cervical cancer (CC) risk. The 9-valent HPV (9vHPV) vaccine has high demonstrated effectiveness against HPV types causing 90% of CC. Additionally, one dose of the 9vHPV vaccine has the potential to achieve greater coverage at lower costs than a two-dose schedule. However, the potential impact of single-dose 9vHPV vaccine accounting for HPV-HIV interactions has not been estimated.
methodsWe adapted a dynamic HIV transmission model to include HPV acquisition and CC pathogenesis and projected the impact of a single dose 9vHPV preadolescent vaccination in KwaZulu-Natal, South Africa. We report health impacts of HPV vaccination separately for HIV-positive women stratified by HIV treatment and CD4 count and HIV-negative women.
resultsAt 90% coverage of females age 9 years with 80% lifelong vaccine efficacy, single dose HPV vaccination was projected to reduce CC incidence by 74% and mortality by 71% in the general female population at 70 years after the start of the vaccination program. Age-standardized CC incidence and mortality reductions were comparable among HIV-negative women, HIV-positive women, and HIV-positive women on ART. Health benefits were reduced when assuming waning protection at 10, 15 and 20 years after vaccination. DISCUSSION: Single dose 9vHPV vaccination is projected to avert substantial CC burden in South Africa and similar high HIV prevalence settings. Health benefits were comparable across all female subpopulations stratified by HIV status, CD4 count, and ART status.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.